{"id":"dmt-continuation","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This represents a continuation phase study evaluating the sustained efficacy and safety of a disease-modifying treatment (DMT) in multiple sclerosis. The specific mechanism depends on the underlying DMT being continued, which could involve immunomodulation, immune suppression, or other pathways targeting MS pathophysiology. Phase 3 continuation studies typically assess long-term outcomes and tolerability in patients who have completed initial treatment phases.","oneSentence":"DMT continuation refers to the ongoing administration of disease-modifying therapy in multiple sclerosis patients to maintain therapeutic benefit and prevent disease progression.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:46.046Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (continuation of disease-modifying therapy)"}]},"trialDetails":[{"nctId":"NCT06663189","phase":"PHASE3","title":"Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-01","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":200},{"nctId":"NCT04754542","phase":"","title":"Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-05-18","conditions":"Multiple Sclerosis","enrollment":76},{"nctId":"NCT03653273","phase":"PHASE3","title":"Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)","status":"RECRUITING","sponsor":"Rennes University Hospital","startDate":"2019-01-24","conditions":"Multiple Sclerosis","enrollment":250},{"nctId":"NCT05500651","phase":"NA","title":"Dance and Movement Therapy in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Amasya University","startDate":"2022-09-01","conditions":"Schizophrenia, Negative Symptoms in Schizophrenia, Disabilities Mental","enrollment":30},{"nctId":"NCT04260711","phase":"NA","title":"Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-07-01","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DMT continuation","genericName":"DMT continuation","companyName":"Rennes University Hospital","companyId":"rennes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DMT continuation refers to the ongoing administration of disease-modifying therapy in multiple sclerosis patients to maintain therapeutic benefit and prevent disease progression. Used for Multiple sclerosis (continuation of disease-modifying therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}